Treatment with low-dose nintedanib and tacrolimus in patients with progressive fibrosing interstitial lung diseases with anti-ARS antibody-positive dermatomyositis

被引：0

作者：

Kawaguchi, Takeshi ^{[1
]}

Matsuda, Motohiro ^{[1
]}

Umekita, Kunihiko ^{[1
]}

Miyazaki, Taiga ^{[1
]}

机构：

[1] Univ Miyazaki, Fac Med, Dept Internal Med, Div Respirol Rheumatol Infect Dis & Neurol, 5200 Kihara, Miyazaki 8891692, Japan

来源：

RESPIROLOGY CASE REPORTS | 2024年 / 12卷 / 07期

关键词：

connective tissue diseases; nintedanib; P-glycoprotein; progressive fibrosing interstitial lung diseases; tacrolimus;

D O I：

10.1002/rcr2.1428

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

Nintedanib has been demonstrated to inhibit the rate of forced vital capacity decline in patients with progressive fibrosing interstitial lung diseases (PF-ILD) at a dose of 200 or 300 mg/day in the INBUILD trial. Although concomitant use of nintedanib with P-glycoprotein inhibitors reportedly increases the plasma concentrations of the former, tacrolimus, a P-glycoprotein inhibitor, is often used to treat connective tissue diseases-related interstitial lung diseases. The optimal dose of nintedanib in combination with tacrolimus for the treatment of PF-ILD with connective tissue disease is unknown. We herein present two patients with PF-ILD with anti-aminoacyl-tRNA synthetase antibody-positive dermatomyositis who were successfully treated with low-dose nintedanib (<200 mg/day) in combination with tacrolimus.

引用

页数：4

共 5 条

[1] Nintedanib in Progressive Fibrosing Interstitial Lung Diseases [J].

Flaherty, K. R. ;

Wells, A. U. ;

Cottin, V ;

Devaraj, A. ;

Walsh, S. L. F. ;

Inoue, Y. ;

Richeldi, L. ;

Kolb, M. ;

Tetzlaff, K. ;

Stowasser, S. ;

Coeck, C. ;

Clerisme-Beaty, E. ;

Rosenstock, B. ;

Quaresma, M. ;

Haeufel, T. ;

Goeldner, R-G ;

Schlenker-Herceg, R. ;

Brown, K. K. .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (18) :1718-1727

[2] The efficacy of tacrolimus in patients with interstitial lung diseases complicated with polymyositis or dermatomyositis [J].

Kurita, Takashi ;

Yasuda, Shinsuke ;

Oba, Koji ;

Odani, Toshio ;

Kono, Michihito ;

Otomo, Kotaro ;

Fujieda, Yuichiro ;

Oku, Kenji ;

Bohgaki, Toshiyuki ;

Amengual, Olga ;

Horita, Tetsuya ;

Atsumi, Tatsuya .

RHEUMATOLOGY, 2015, 54 (01) :39-44

[3] Real-World Safety and Tolerability of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Interim Report of a Post-Marketing Surveillance in Japan [J].

Ogura, Takashi ;

Inoue, Yoshikazu ;

Azuma, Arata ;

Homma, Sakae ;

Kondoh, Yasuhiro ;

Tanaka, Katsumi ;

Ochiai, Kaori ;

Sugiyama, Yukihiko ;

Nukiwa, Toshihiro .

ADVANCES IN THERAPY, 2023, 40 (04) :1474-1493

[4] Antisynthetase syndrome: Pulmonary computed tomography findings of adult patients with antibodies to aminoacyl-tRNA synthetases [J].

Waseda, Yuko ;

Johkoh, Takeshi ;

Egashira, Ryoko ;

Sumikawa, Hiromitsu ;

Saeki, Keigo ;

Watanabe, Satoshi ;

Matsunuma, Ryo ;

Takato, Hazuki ;

Ichikawa, Yukari ;

Hamaguchi, Yasuhito ;

Shiraki, Akira ;

Muro, Yoshinao ;

Yasui, Masahide ;

Prosch, Helmut ;

Herold, Christian ;

Kasahara, Kazuo .

EUROPEAN JOURNAL OF RADIOLOGY, 2016, 85 (08) :1421-1426

[5] Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib [J].

Wind, Sven ;

Schmid, Ulrike ;

Freiwald, Matthias ;

Marzin, Kristell ;

Lotz, Ralf ;

Ebner, Thomas ;

Stopfer, Peter ;

Dallinger, Claudia .

CLINICAL PHARMACOKINETICS, 2019, 58 (09) :1131-1147

← 1 →